SK382003A3 - Use of strains of the Parapox ovis virus against organ fibrosis - Google Patents

Use of strains of the Parapox ovis virus against organ fibrosis Download PDF

Info

Publication number
SK382003A3
SK382003A3 SK38-2003A SK382003A SK382003A3 SK 382003 A3 SK382003 A3 SK 382003A3 SK 382003 A SK382003 A SK 382003A SK 382003 A3 SK382003 A3 SK 382003A3
Authority
SK
Slovakia
Prior art keywords
humans
organ fibrosis
cells
manufacture
medicaments
Prior art date
Application number
SK38-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK382003A3 publication Critical patent/SK382003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK38-2003A 2000-07-11 2001-07-11 Use of strains of the Parapox ovis virus against organ fibrosis SK382003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (1)

Publication Number Publication Date
SK382003A3 true SK382003A3 (en) 2003-07-01

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
SK38-2003A SK382003A3 (en) 2000-07-11 2001-07-11 Use of strains of the Parapox ovis virus against organ fibrosis

Country Status (30)

Country Link
US (1) US6632647B2 (zh)
EP (1) EP1303302B1 (zh)
JP (1) JP5106736B2 (zh)
CN (1) CN1452496B (zh)
AR (1) AR028800A1 (zh)
AU (2) AU8582701A (zh)
BG (1) BG107447A (zh)
CA (1) CA2415399C (zh)
CZ (1) CZ200372A3 (zh)
DK (1) DK200300014A (zh)
EE (1) EE200300019A (zh)
FI (1) FI20030038A (zh)
GB (1) GB2383752B (zh)
HK (1) HK1054330B (zh)
HR (1) HRP20030097A2 (zh)
HU (1) HU227668B1 (zh)
IL (1) IL153826A0 (zh)
LT (1) LT5064B (zh)
LU (1) LU90996B1 (zh)
LV (1) LV12991B (zh)
MA (1) MA25765A1 (zh)
MX (1) MXPA03000278A (zh)
NO (1) NO20030081L (zh)
NZ (1) NZ523535A (zh)
PL (1) PL360839A1 (zh)
RU (1) RU2003104522A (zh)
SE (1) SE0300033L (zh)
SI (1) SI21171A (zh)
SK (1) SK382003A3 (zh)
WO (1) WO2002004019A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
CA3018307A1 (en) * 2016-02-16 2017-08-24 Osaka University Pharmaceutical composition for use in treating fibrosis
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1997038724A1 (de) * 1996-04-15 1997-10-23 Anton Mayr Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
IL153826A0 (en) 2003-07-31
JP5106736B2 (ja) 2012-12-26
HK1054330A1 (en) 2003-11-28
NO20030081D0 (no) 2003-01-08
GB2383752A (en) 2003-07-09
WO2002004019A3 (de) 2002-08-01
HK1054330B (zh) 2005-07-15
AU2001285827B2 (en) 2006-11-30
SI21171A (sl) 2003-10-31
LV12991B (en) 2003-08-20
MA25765A1 (fr) 2003-04-01
US20020076418A1 (en) 2002-06-20
HRP20030097A2 (en) 2005-02-28
AU8582701A (en) 2002-01-21
JP2004502741A (ja) 2004-01-29
CA2415399C (en) 2011-11-08
AR028800A1 (es) 2003-05-21
HUP0303830A3 (en) 2004-10-28
BG107447A (bg) 2003-09-30
EE200300019A (et) 2004-10-15
CN1452496A (zh) 2003-10-29
GB0302629D0 (en) 2003-03-12
SE0300033D0 (sv) 2003-01-10
LU90996B1 (en) 2003-01-08
CA2415399A1 (en) 2003-01-08
WO2002004019A2 (de) 2002-01-17
HUP0303830A2 (hu) 2004-04-28
HU227668B1 (en) 2011-11-28
MXPA03000278A (es) 2004-04-05
NZ523535A (en) 2004-12-24
CZ200372A3 (cs) 2003-05-14
US6632647B2 (en) 2003-10-14
EP1303302B1 (de) 2009-10-14
LT5064B (lt) 2003-11-25
GB2383752B (en) 2004-11-24
LT2003008A (en) 2003-07-25
EP1303302A2 (de) 2003-04-23
NO20030081L (no) 2003-01-08
CN1452496B (zh) 2012-10-10
SE0300033L (sv) 2003-03-10
RU2003104522A (ru) 2004-06-27
FI20030038A (fi) 2003-03-10
DK200300014A (da) 2003-03-07
PL360839A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
SK382003A3 (en) Use of strains of the Parapox ovis virus against organ fibrosis
JP5950964B2 (ja) 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
JP5665899B2 (ja) 癌の処置のための粘液腫ウイルス変異体
EP4198043A1 (en) Method for producing an antigen corresponding to the inactivated sars-cov-2 virus, antigen corresponding to the inactivated sars-cov-2 virus, antigenic composition, kits, and uses thereof
Koelsch et al. Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline
CN112472791A (zh) CsA脂质体在制备抗SARS-CoV-2药物中的应用
WO2022000167A1 (zh) 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
WO2017141942A1 (ja) 線維化を治療するための医薬組成物
US20230398177A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
EP4331598A1 (en) Antiviral fungal extracts
CN117122693A (zh) 经酸酐修饰的蛋白质抑制痘病毒的方法
WO2021224836A1 (en) A synergistic formulation for management of respiratory pathogens including coronaviruses
CN113521099A (zh) 锌离子在抗肠道病毒ev-d68中的应用
CN115475196A (zh) 腹安颗粒浸膏在制备用于治疗手足口病的药物中的用途
CZ308937B6 (cs) Použití hem arginátu pro výrobu léčiva pro léčbu infekce beta koronaviry
WO2016133560A1 (en) Recombinant human cc10 protein for treatment of influenza and ebola

Legal Events

Date Code Title Description
FC9A Refused patent application